KR20230144529A - 키나아제 억제제 및 이의 용도 - Google Patents
키나아제 억제제 및 이의 용도 Download PDFInfo
- Publication number
- KR20230144529A KR20230144529A KR1020237024086A KR20237024086A KR20230144529A KR 20230144529 A KR20230144529 A KR 20230144529A KR 1020237024086 A KR1020237024086 A KR 1020237024086A KR 20237024086 A KR20237024086 A KR 20237024086A KR 20230144529 A KR20230144529 A KR 20230144529A
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- compound
- acceptable salt
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126364P | 2020-12-16 | 2020-12-16 | |
| US63/126,364 | 2020-12-16 | ||
| PCT/US2021/063724 WO2022133040A1 (en) | 2020-12-16 | 2021-12-16 | Kinase inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230144529A true KR20230144529A (ko) | 2023-10-16 |
Family
ID=79425572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237024086A Pending KR20230144529A (ko) | 2020-12-16 | 2021-12-16 | 키나아제 억제제 및 이의 용도 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240083844A1 (https=) |
| EP (1) | EP4263501A1 (https=) |
| JP (1) | JP2023554391A (https=) |
| KR (1) | KR20230144529A (https=) |
| CN (1) | CN117083265A (https=) |
| AU (1) | AU2021401282A1 (https=) |
| CA (1) | CA3179325A1 (https=) |
| MX (1) | MX2023006434A (https=) |
| WO (1) | WO2022133040A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116356017A (zh) * | 2022-12-12 | 2023-06-30 | 南京腾辰生物科技有限公司 | 一种甲状腺肿瘤良恶性早期诊断标志物及其应用 |
| WO2025184877A1 (zh) * | 2024-03-07 | 2025-09-12 | 中国医学科学院基础医学研究所 | 新免疫检查点grhl3在癌症诊疗和免疫治疗疗效评价中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200703912B (en) * | 2004-10-20 | 2008-09-25 | Serono Lab | 3-arylamino pyridine derivatives |
| GB0812913D0 (en) * | 2008-07-15 | 2008-08-20 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN102666512B (zh) * | 2009-10-13 | 2014-11-26 | 奥斯特姆医疗公司 | 对疾病治疗有用的mek抑制剂 |
| WO2012055953A1 (en) * | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
| AU2013266438B2 (en) * | 2012-05-22 | 2017-09-07 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
| WO2019006548A1 (en) * | 2017-07-04 | 2019-01-10 | Trillium Therapeutics Inc. | FLUORINATED 2,4-DIAMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE MER (MERTK) AND USES THEREOF |
-
2021
- 2021-12-16 AU AU2021401282A patent/AU2021401282A1/en active Pending
- 2021-12-16 WO PCT/US2021/063724 patent/WO2022133040A1/en not_active Ceased
- 2021-12-16 US US18/266,793 patent/US20240083844A1/en active Pending
- 2021-12-16 MX MX2023006434A patent/MX2023006434A/es unknown
- 2021-12-16 EP EP21841148.6A patent/EP4263501A1/en active Pending
- 2021-12-16 CA CA3179325A patent/CA3179325A1/en active Pending
- 2021-12-16 JP JP2023536389A patent/JP2023554391A/ja active Pending
- 2021-12-16 CN CN202180084903.0A patent/CN117083265A/zh active Pending
- 2021-12-16 KR KR1020237024086A patent/KR20230144529A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4263501A1 (en) | 2023-10-25 |
| JP2023554391A (ja) | 2023-12-27 |
| MX2023006434A (es) | 2023-06-13 |
| WO2022133040A1 (en) | 2022-06-23 |
| CA3179325A1 (en) | 2022-06-23 |
| CN117083265A (zh) | 2023-11-17 |
| US20240083844A1 (en) | 2024-03-14 |
| AU2021401282A1 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116249683B (zh) | 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用 | |
| CN112778284B (zh) | 一种嘧啶并环衍生物及其在医药上的应用 | |
| CN115836070B (zh) | 作为egfr抑制剂的稠环化合物及其制备方法和应用 | |
| RU2687060C2 (ru) | Фармацевтические соединения | |
| EP3191472B1 (en) | Compounds and compositions as raf kinase inhibitors | |
| EP3684772B1 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| KR102682216B1 (ko) | 칸나비노이드 수용체 조절제 | |
| WO2025002430A1 (zh) | 一种5元杂芳基衍生物及其在医药上的应用 | |
| KR20190086442A (ko) | 피리딘 화합물 | |
| WO2022037630A1 (zh) | 四环类衍生物、其制备方法及其医药上的用途 | |
| WO2019189555A1 (ja) | 複素環化合物 | |
| WO2024193464A1 (zh) | 一种含氮三并环衍生物及其在医药上的应用 | |
| CN110028507A (zh) | 具有trk激酶抑制活性化合物、制备方法、组合物及用途 | |
| KR20230144529A (ko) | 키나아제 억제제 및 이의 용도 | |
| CN110156783B (zh) | 作为pi3k/mtor抑制剂的嘧啶基取代的稠合喹啉化合物 | |
| KR102668390B1 (ko) | 신규한 pan-RAF 키나아제 저해제 및 이의 용도 | |
| CN111518082B (zh) | 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途 | |
| CN113166109B (zh) | 氨基吡啶类化合物及其制备方法和用途 | |
| WO2025103489A1 (zh) | 一种hpk1降解剂及其在医药上的应用 | |
| CN109111439B (zh) | 一种酰胺类化合物及包含该化合物的组合物及其用途 | |
| KR20170095243A (ko) | Pi3kbeta 저해제로서의 헤테로사이클릴 연결된 이미다조피리다진 유도체 | |
| CN118255780A (zh) | 一种抑制并降解c-MYC的化合物及其医药上的应用 | |
| HK40103623A (zh) | 激酶抑制剂及其用途 | |
| RU2801302C2 (ru) | Производные циклического иминопиримидина в качестве ингибиторов киназ | |
| RU2792626C1 (ru) | Новый ингибитор киназы pan-raf и его применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 |